sign in sign up
<<
Home , Norlevorphanol

MISSISSIPPI LEGISLATURE REGULAR SESSION 2019

By: Representative Chism To: Drug Policy

HOUSE BILL NO. 1142

1 AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972, 2 TO EXCLUDE HEMP-DERIVED (CBD) OIL FROM THE SCHEDULE I 3 CONTROLLED SUBSTANCES LIST; AND FOR RELATED PURPOSES. 4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

5 SECTION 1. Section 41-29-113, Mississippi Code of 1972, is 6 amended as follows:

7 41-29-113. The controlled substances listed in this section 8 are included in Schedule I.

9 SCHEDULE I 10 (a) Opiates. Any of the following opiates, including their 11 isomers, esters, ethers, salts and salts of isomers, esters and 12 ethers, unless specifically excepted, whenever the existence of 13 these isomers, esters, ethers and salts is possible within the

14 specific chemical designation: 15 (1) Acetyl-alpha-methylfentanyl; 16 (2) Acetyl 17 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide;

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ G1/2 19/HR43/R863 PAGE 1 (RKM\EW) 18 (3) AH-7921 (3,4-dichloro-N-[(1-dimethylamino) 19 cyclohexylmethyl]benzamide); 20 (4) Acetylmethadol; 21 (5) Allylprodine; 22 (6) Alphacetylmethadol, except levo-alphacetylmethadol 23 (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);

24 (7) Alphameprodine; 25 (8) Alphamethadol; 26 (9) Alpha-methylfentanyl; 27 (10) Alpha-methylthiofentanyl; 28 (11) Benzethidine; 29 (12) Betacetylmethadol; 30 (13) Beta-hydroxyfentanyl;

31 (14) Beta-hydroxy-3-methylfentanyl; 32 (15) Betameprodine; 33 (16) Betamethadol; 34 (17) Betaprodine; 35 (18) Clonitazene;

36 (19) ; 37 (20) Diampromide;

38 (21) Diethylthiambutene; 39 (22) Difenoxin; 40 (23) ; 41 (24) Dimepheptanol; 42 (25) Dimethylthiambutene;

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ 19/HR43/R863 PAGE 2 (RKM\EW) 43 (26) Dioxaphetyl butyrate; 44 (27) ; 45 (28) Ethylmethylthiambutene; 46 (29) Etonitazene; 47 (30) Etoxeridine; 48 (31) Furanyl Fentanyl,

49 N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide; 50 (32) Furethidine; 51 (33) Hydroxypethidine; 52 (34) ; 53 (35) Levomoramide; 54 (36) ; 55 (37) 3-methylfentanyl;

56 (38) 3-methylthiofentanyl; 57 (39) Morpheridine; 58 (40) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);

59 (41) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, 60 its isomers, esters, ethers, salts and salts of isomers, esters

61 and ethers (other names: Butyryl fentanyl); 62 (42)

63 N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylprop 64 ionamide, its isomers, esters, ethers, salts and salts of isomers, 65 esters and ethers (other names: beta-hydroxythiofentanyl); 66 (43) Noracymethadol; 67 (44) Norlevorphanol;

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ 19/HR43/R863 PAGE 3 (RKM\EW) 68 (45) Normethadone; 69 (46) Norpipanone; 70 (47) Para-fluorofentanyl; 71 (48) PEPAP 72 (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine); 73 (49) Phenadoxone;

74 (50) Phenampromide; 75 (51) Phenomorphan; 76 (52) Phenoperidine; 77 (53) ; 78 (54) Proheptazine; 79 (55) Properidine; 80 (56) ;

81 (57) Racemoramide; 82 (58) Thiofentanyl; 83 (59) ; 84 (60) Trimeperidine; 85 (61) U-47700,

86 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide.

87 (b) derivatives. Any of the following opium 88 derivatives, their salts, isomers and salts of isomers, unless 89 specifically excepted, whenever the existence of these salts, 90 isomers and salts of isomers is possible within the specific 91 chemical designation: 92 (1) Acetorphine;

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ 19/HR43/R863 PAGE 4 (RKM\EW) 93 (2) ; 94 (3) ; 95 (4) methylbromide; 96 (5) Codeine-N-Oxide; 97 (6) ; 98 (7) ;

99 (8) ; 100 (9) Drotebanol; 101 (10) (except hydrochloride salt); 102 (11) ; 103 (12) ; 104 (13) Methyldesorphine; 105 (14) Methyldihydromorphine;

106 (15) Monoacetylmorphine; 107 (16) methylbromide; 108 (17) Morphine methylsulfonate; 109 (18) Morphine-N-Oxide; 110 (19) Myrophine;

111 (20) ; 112 (21) ;

113 (22) Normorphine; 114 (23) Pholcodine; 115 (24) Thebacon.

116 (c) Hallucinogenic substances. Any material, compound, 117 mixture or preparation which contains any quantity of the

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ 19/HR43/R863 PAGE 5 (RKM\EW) 118 following substances, their salts, isomers (whether optical, 119 positional, or geometric) and salts of isomers, unless 120 specifically excepted, whenever the existence of these salts, 121 isomers and salts of isomers is possible within the specific 122 chemical designation: 123 (1) Alpha-ethyltryptamine;

124 (2) 4-bromo-2,5-dimethoxy-amphetamine; 125 (3) 4-bromo-2,5-dimethoxyphenethylamine; 126 (4) 2,5-dimethoxyamphetamine; 127 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET); 128 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine 129 2C-T-7); 130 (7) 4-methoxyamphetamine;

131 (8) 5-methoxy-3,4-methylenedioxy-amphetamine; 132 (9) 4-methyl-2,5-dimethoxy-amphetamine; 133 (10) 3,4-methylenedioxy amphetamine; 134 (11) 3,4-methylenedioxymethamphetamine (MDMA); 135 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known

136 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl 137 MDA, MDE, MDEA);

138 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also 139 known as N-hydroxy MDA, N-OHMDA, and 140 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine); 141 (14) 3,4,5-trimethoxy amphetamine; 142 (15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ 19/HR43/R863 PAGE 6 (RKM\EW) 143 (16) Alpha-methyltryptamine (also known as AMT); 144 (17) Bufotenine; 145 (18) Diethyltryptamine; 146 (19) Dimethyltryptamine; 147 (20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT); 148 (21) ;

149 (22) Lysergic acid diethylamide (LSD); 150 (23) (A) Marijuana (Cannabidiol contained in a legend 151 drug product approved by the Federal Food and Drug Administration 152 or obtained under Section 41-29-136 is exempt under Schedule I); 153 (B) Hashish; 154 (24) Mescaline; 155 (25) Parahexyl;

156 (26) Peyote; 157 (27) N-ethyl-3-piperidyl benzilate; 158 (28) N-methyl-3-piperidyl benzilate; 159 (29) Psilocybin; 160 (30) Psilocyn;

161 (31) , meaning 162 tetrahydrocannabinols contained in a plant of the genus Cannabis

163 (cannabis plant), as well as the synthetic equivalents of the 164 substances contained in the cannabis plant, or in the resinous 165 extractives of such plant, and/or synthetic substances, 166 derivatives, and their isomers with similar chemical structure and

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ 19/HR43/R863 PAGE 7 (RKM\EW) 167 pharmacological activity to those substances contained in the 168 plant such as the following: 169 (A) 1 cis or trans ; 170 (B) 6 cis or trans tetrahydrocannabinol; 171 (C) 3,4 cis or trans tetrahydrocannabinol. 172 (Since nomenclature of these substances is not

173 internationally standardized, compounds of these structures, 174 regardless of atomic positions are covered.) 175 ("Tetrahydrocannabinols" excludes dronabinol and nabilone.) 176 However, the following products are exempted from control: 177 (i) THC-containing industrial products made 178 from cannabis stalks (e.g., paper, rope and clothing); 179 (ii) Processed cannabis plant materials used

180 for industrial purposes, such as fiber retted from cannabis stalks 181 for use in manufacturing textiles or rope; 182 (iii) Animal feed mixtures that contain 183 sterilized cannabis seeds and other ingredients (not derived from 184 the cannabis plant) in a formula designed, marketed and

185 distributed for nonhuman consumption; 186 (iv) Personal care products that contain oil

187 from sterilized cannabis seeds, such as shampoos, soaps, and body 188 lotions (if the products do not cause THC to enter the human

189 body); * * * 190 (v) Processed cannabis plant extract, oil or 191 resin with a minimum ratio of twenty-to-one cannabidiol to

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ 19/HR43/R863 PAGE 8 (RKM\EW) 192 tetrahydrocannabinol (20:1 cannabidiol:tetrahydrocannabinol), and 193 diluted so as to contain at least fifty (50) milligrams of 194 cannabidiol per milliliter, with not more than two and one-half 195 (2.5) milligrams of tetrahydrocannabinol per milliliter; and 196 (vi) Processed hemp-derived cannabidiol (CBD) 197 oil, which may not contain more than three-tenths percent (0.3%)

198 tetrahydrocannabinol (THC); 199 (32) ; 200 (33) Ethylamine analog of phencyclidine (PCE); 201 (34) Pyrrolidine analog of phencyclidine (PHP, PCPy); 202 (35) Thiophene analog of phencyclidine; 203 (36) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine (TCPy); 204 (37) 4-methylmethcathinone (mephedrone);

205 (38) 3,4-methylenedioxypyrovalerone (MDPV); 206 (39) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E); 207 (40) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D); 208 (41) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); 209 (42) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);

210 or 2,5-dimethoxy-4-iodophenethylamine; 211 (43) 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine

212 (2C-T-2); 213 (44) 214 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4); 215 (45) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H); 216 (46) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N);

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ 19/HR43/R863 PAGE 9 (RKM\EW) 217 (47) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine 218 (2C-P); 219 (48) 3,4-methylenedioxy-N-methylcathinone(methylone); 220 (49) 221 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine 222 (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);

223 (50) 224 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine 225 (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); 226 (51) 227 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or 228 N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; 229 Cimbi-5);

230 (52) 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1, 231 4-benzodiazepin-2-one (also known as Phenazepam); 232 (53) 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8, 233 11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene 234 (also known as Etizolam);

235 (54) ; 236 (55) Synthetic cannabinoids. Unless specifically

237 excepted or unless listed in another schedule, any material, 238 compound, mixture, or preparation which contains any quantity of a 239 synthetic cannabinoid found in any of the following chemical 240 groups, whether or not substituted to any extent, or any of those 241 groups which contain any synthetic cannabinoid salts, isomers, or

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ 19/HR43/R863 PAGE 10 (RKM\EW) 242 salts of isomers, whenever the existence of such salts, isomers, 243 or salts of isomers is possible within the specific chemical 244 designation, including all synthetic cannabinoid chemical 245 analogues in such groups: 246 (A) (6aR,10aR)-9-(hydroxymethyl)-6, 247 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]

248 chromen-1-ol (also known as HU-210 or 249 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol); 250 (B) Naphthoylindoles and naphthylmethylindoles, 251 being any compound structurally derived from 3-(1-naphthoyl)indole 252 or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted 253 in the indole ring to any extent, or in the naphthyl ring to any 254 extent;

255 (C) Naphthoylpyrroles, being any compound 256 structurally derived from 3-(1-naphthoyl)pyrrole, whether or not 257 substituted in the pyrrole ring to any extent, or in the naphthyl 258 ring to any extent; 259 (D) Naphthylmethylindenes, being any compound

260 structurally derived from 1-(1-naphthylmethyl)indene, whether or 261 not substituted in the indene ring to any extent or in the

262 naphthyl ring to any extent; 263 (E) Phenylacetylindoles, being any compound 264 structurally derived from 3-phenylacetylindole, whether or not 265 substituted in the indole ring to any extent or in the phenyl ring 266 to any extent;

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ 19/HR43/R863 PAGE 11 (RKM\EW) 267 (F) Cyclohexylphenols, being any compound 268 structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether

269 or not substituted in the cyclohexyl ring to any extent or in the 270 phenolic ring to any extent; 271 (G) Benzoylindoles, whether or not substituted in 272 the indole ring to any extent or in the phenyl ring to any extent;

273 (H) Adamantoylindoles, whether or not substituted 274 in the indole ring to any extent or in the adamantoyl ring system 275 to any extent; 276 (I) Tetrahydro derivatives of cannabinol and 277 3-alkyl homologues of cannabinol or of its tetrahydro derivatives, 278 except where contained in cannabis or cannabis resin; 279 (J) 3-Cyclopropylmethanone indole or

280 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by 281 substitution at the nitrogen atom of the indole ring, whether or 282 not further substituted in the indole ring to any extent, whether 283 or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl 284 rings to any extent;

285 (K) Quinolinyl ester indoles, being any compound 286 structurally derived from 1H-indole-3carboxylic acid-8-quinolinyl

287 ester, whether or not substituted in the indole ring to any extent 288 or the quinolone ring to any extent; 289 (L) 3-carboxamide-1H-indazoles, whether or not 290 substituted in the indazole ring to any extent and substituted to 291 any degree on the carboxamide nitrogen and

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ 19/HR43/R863 PAGE 12 (RKM\EW) 292 3-carboxamide-1H-indoles, whether or not substituted in the indole 293 ring to any extent and substituted to any degree on the 294 carboxamide nitrogen; 295 (M) Cycloalkanemethanone Indoles, whether or not 296 substituted at the nitrogen atom on the indole ring, whether or 297 not further substituted in the indole ring to any extent, whether

298 or not substituted on the cycloalkane ring to any extent.

299 (d) Depressants. Unless specifically excepted or unless 300 listed in another schedule, any material, compound, mixture, or 301 preparation which contains any quantity of the following 302 substances having a depressant effect on the central nervous 303 system, including their salts, isomers, and salts of isomers, 304 whenever the existence of such salts, isomers, and salts of

305 isomers is possible within the specific chemical designation: 306 (1) Gamma-hydroxybutyric acid (other names include: 307 GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic 308 acid; sodium oxybate; sodium oxybutyrate); 309 (2) Mecloqualone;

310 (3) Methaqualone.

311 (e) Stimulants. Any material, compound, mixture or 312 preparation which contains any quantity of the following central 313 nervous system stimulants including optical salts, isomers and 314 salts of isomers unless specifically excepted or unless listed in 315 another schedule: 316 (1) Aminorex;

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ 19/HR43/R863 PAGE 13 (RKM\EW) 317 (2) N-benzylpiperazine (also known as BZP * * * and 318 1-benzylpiperazine); 319 (3) Cathinone; 320 (4) Fenethylline; 321 (5) Methcathinone; 322 (6) 4-methylaminorex (also known as

323 2-amino-4-methyl-5-phenyl-2-oxazoline); 324 (7) N-ethylamphetamine; 325 (8) Any material, compound, mixture or preparation 326 which contains any quantity of N,N-dimethylamphetamine. (Other

327 names include: N,N,-alpha-trimethyl-benzeneethanamine * * * and 328 N,N-alphatrimethylphenethylamine);

329 (9) Synthetic cathinones. (A) Unless listed in 330 another schedule, any compound other than bupropion that is 331 structurally derived from 2-Amino-1-phenyl-1-propanone by 332 modification in any of the following ways: 333 (i) By substitution in the phenyl ring to any 334 extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide

335 substituents, whether or not further substituted in the phenyl 336 ring by one or more other univalent substituents;

337 (ii) By substitution at the 3-position with 338 an alkyl substituent; 339 (iii) By substitution at the nitrogen atom 340 with alkyl or dialkyl groups, or by inclusion of the nitrogen atom 341 in a cyclic structure.

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ 19/HR43/R863 PAGE 14 (RKM\EW) 342 (B) The compounds covered in this paragraph (9) 343 include, but are not limited to, any material compound, mixture or 344 preparation which contains any quantity of a synthetic cathinone 345 found in any of the following compounds, whether or not 346 substituted to any extent, or any of these compounds which contain 347 any synthetic cathinone, or salts, isomers, or salts of isomers,

348 whenever the existence of such salts, isomers or salts of isomers 349 is possible, unless specifically excepted or listed in another 350 schedule: 351 (i) 4-methyl-N-ethylcathinone ("4-MEC"); 352 (ii) 4-methyl-alpha-pyrrolidinopropiophenone 353 ("4-MePPP"); 354 (iii) Alpha-pyrrolidinopentiophenone

355 ("α-PVP"); 356 (iv) 357 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one ("butylone"); 358 (v) 2-(methylamino)-1-phenylpentan-1-one 359 ("pentedrone");

360 (vi) 361 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one

362 ("pentylone"); 363 (vii) 4-fluoro-N-methylcathinone ("4-FMC"); 364 (viii) 3-fluoro-N-methylcathinone ("3-FMC");

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ 19/HR43/R863 PAGE 15 (RKM\EW) 365 (ix) 366 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one ("naphyrone"); 367 and 368 (x) Alpha-pyrrolidinobutiophenone ("α-PBP").

369 SECTION 2. This act shall take effect and be in force from 370 and after July 1, 2019.

H. B. No. 1142 *HR43/R863* ~ OFFICIAL ~ 19/HR43/R863 ST: Hemp-derived CBD oil; exclude from schedule PAGE 16 (RKM\EW) I controlled substances list.